New Drug Reverses Anticoagulant Effects of Blood Thinner
News Jul 16, 2015
Dabigatran, sold under the brand name Pradaxa, is a blood-thinner used to prevent strokes in patients with the heart condition atrial fibrillation.
The study enrolled 90 patients at 184 sites in 35 countries, including Northwestern Medicine. Unlike warfarin, but similarly to other members of the class of Novel Oral Anticoagulants, there are no currently approved reversal agents for dabigatran.
“Dabigatran prevents strokes better than warfarin with less bleeding in the brain, but one problem with dabigatran and other novel anticoagulants was that there was no reversal agent,” said Richard A Bernstein, MD, PhD, a co-author and professor in Neurology – Ken and Ruth Davee Department. “Some clinicians were wary of using this class of medications because there was no way to turn it off.”
Idarucizumab is given intravenously and binds to dabigatran. Within minutes of administration, the anticoagulant effect of dabigatran was completely reversed in the first 90 patients enrolled in this study.
“The advent of this reversal agent should provide both patients and physicians with peace of mind when taking dabigatran,” Dr. Bernstein said. “Its always good to have a way to turn off the effect of this blood thinner in emergencies.”
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019